Glaucoma surgical procedures under development.
Journal
Current opinion in ophthalmology
ISSN: 1531-7021
Titre abrégé: Curr Opin Ophthalmol
Pays: United States
ID NLM: 9011108
Informations de publication
Date de publication:
15 Dec 2023
15 Dec 2023
Historique:
medline:
18
12
2023
pubmed:
18
12
2023
entrez:
18
12
2023
Statut:
aheadofprint
Résumé
Rapid innovation in glaucoma surgery is expanding surgical options in the angle, subconjunctival space, and supraciliary space. Advancements in glaucoma surgery make it possible for surgeons to provide treatments with less risk. In particular, new devices and lasers are available for minimally invasive glaucoma surgeries. There are also new implants and techniques for bleb-forming glaucoma surgery. As glaucoma surgeons have access to an increasing number of procedures, devices, and treatments, it is important for evidence to drive decision-making.
Identifiants
pubmed: 38108372
doi: 10.1097/ICU.0000000000001020
pii: 00055735-990000000-00142
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Rathi S, Andrews CA, Greenfield DS, Stein JD. Trends in glaucoma surgeries performed by glaucoma subspecialists versus nonsubspecialists on Medicare beneficiaries from 2008 through 2016. Ophthalmology 2021; 128:30–38.
Ventura-Abreu N, García-Feijoo J, Pazos M, et al. Twelve-month results of ab interno trabeculectomy with Kahook Dual Blade: an interventional, randomized, controlled clinical study. Graefes Arch Clin Exp Ophthalmol 2021; 259:2771–2781.
Deubel C, Böhringer D, Anton A, et al. Long-term follow-up of intraocular pressure and pressure-lowering medication in patients following Excimer laser trabeculotomy. Graefes Arch Clin Exp Ophthalmol 2021; 259:957–962.
Berlin MS, Shakibkhou J, Tilakaratna N, et al. Eight-year follow-up of excimer laser trabeculostomy alone and combined with phacoemulsification in patients with open-angle glaucoma. J Cataract Refract Surg 2022; 48:838–843.
Nagy ZZ, Kranitz K, Ahmed IIK, et al. First-in-human safety study of femtosecond laser image-guided trabeculotomy for glaucoma treatment. Ophthalmol Sci 2023; 3:100313.
Gallardo MJ, Pyfer MF, Vold SD, et al. Canaloplasty and trabeculotomy combined with phacoemulsification for glaucoma: 12-month results of the GEMINI study. Clin Ophthalmol Auckl NZ 2022; 16:1225–1234.
Lindstrom R, Lewis R, Hornbeak DM, et al. Outcomes following implantation of two second-generation trabecular micro-bypass stents in patients with open-angle glaucoma on one medication: 18-month follow-up. Adv Ther 2016; 33:2082–2090.
Berdahl J, Voskanyan L, Myers JS, et al. Implantation of two second-generation trabecular micro-bypass stents and topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 18-month follow-up. Clin Experiment Ophthalmol 2017; 45:797–802.
Saheb H, Donnenfeld ED, Solomon KD, et al. Five-year outcomes prospective study of two first-generation trabecular micro-bypass stents (iStent®) in open-angle glaucoma. Curr Eye Res 2021; 46:224–231.
Lima FE, Geraissate JC, Ávila MP. A multicenter prospective comparative study evaluating cataract surgery and endoscopic cyclophotocoagulation either with or without iStent inject implantation in Brazilian patients with glaucoma. Int Ophthalmol 2023; 43:1665–1676.
Ahmed IIK, Rhee DJ, Jones J, et al. Three-year findings of the HORIZON Trial: a schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract. Ophthalmology 2021; 128:857–865.
Ahmed IIK, Fea A, Au L, et al. A prospective randomized trial comparing Hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: the COMPARE Study. Ophthalmology 2020; 127:52–61.
Garcìa-Feijoo J, Höh H, Uzunov R, Dickerson JE. Supraciliary microstent in refractory open-angle glaucoma: two-year outcomes from the DUETTE trial. J Ocul Pharmacol Ther 2018; 34:538–542.
Reiss G, Clifford B, Vold S, et al. Safety and effectiveness of CyPass supraciliary micro-stent in primary open-angle glaucoma: 5-year results from the COMPASS XT study. Am J Ophthalmol 2019; 208:219–225.
Denis P, Hirneiß C, Reddy KP, et al. A first-in-human study of the efficacy and safety of MINIject in patients with medically uncontrolled open-angle glaucoma (STAR-I). Ophthalmol Glaucoma 2019; 2:290–297.
Denis P, Hirneiß C, Durr GM, et al. Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial. Br J Ophthalmol 2022; 106:65–70.
Ianchulev T, Weinreb RN, Kamthan G, et al. Biotissue stent forsupraciliary outflow in open-angle glaucoma patients: surgical procedure and first clinical resultsof an aqueous drainage biostent. Br J Ophthalmol 2023; bjo-2022-322536. doi: 10.1136/bjo-2022-322536. [Epub ahead of print].
doi: 10.1136/bjo-2022-322536.
Sheybani A, Vera V, Grover DS, et al. Gel stent versus trabeculectomy: the randomized, multicenter, gold-standard pathway study (GPS) of effectiveness and safety at 12 months. Am J Ophthalmol 2023; 252:306–325.
Lenzhofer M, Motaabbed A, Colvin HP, et al. Five-year follow-up of corneal endothelial cell density after transscleral ab interno glaucoma gel stent implantation. Graefes Arch Clin Exp Ophthalmol 2023; 261:1073–1082.
Lavin-Dapena C, Cordero-Ros R, D’Anna O, Mogollón I. XEN 63 gel stent device in glaucoma surgery: a 5-years follow-up prospective study. Eur J Ophthalmol 2021; 31:1829–1835.
Beckers HJM, Aptel F, Webers CAB, et al. Safety and effectiveness of the PRESERFLO® MicroShunt in primary open-angle glaucoma: results from a 2-year multicenter study. Ophthalmol Glaucoma 2022; 5:195–209.
Fili S, Kontopoulou K, Vastardis I, et al. PreserFloTM MicroShunt versus trabeculectomy in patients with moderate to advanced open-angle glaucoma: 12-month follow-up of a single-center prospective study. Cureus 2022; 14:e28288.
Van Lancker L, Saravanan A, Abu-Bakra M, et al. Clinical outcomes and cost analysis of PreserFlo versus trabeculectomy for glaucoma management in the United Kingdom. Ophthalmol Glaucoma 2023; 6:342–357.
Cantor L, Burgoyne J, Sanders S, et al. The effect of mitomycin C on Molteno implant surgery: a 1-year randomized, masked, prospective study. J Glaucoma 1998; 7:240–246.
De Sousa Peixoto R, Saravananan A, Selvan H, et al. Baerveldt aqueous shunt with or without mitomycin C augmentation: a retrospective comparison study. Ophthalmol Glaucoma 2023; 6:358–365.
Kim NE, Kim SS, Lee JS, et al. Effect of intraoperative mitomycin C on the surgical outcomes of Ahmed glaucoma valve implantation with ciliary sulcus tube placement. Korean J Ophthalmol KJO 2023; 37:216–223.
Kandarakis SA, Papakonstantinou E, Petrou P, et al. One-year randomized comparison of safety and efficacy of trabeculectomy with mitomycin C sub-tenon injection versus mitomycin C-infused sponges. Ophthalmol Glaucoma 2022; 5:77–84.
Bilgic A, Sudhalkar A, Sudhalkar A, et al. Bevacizumab as an adjunct to trabeculectomy in primary open-angle glaucoma: a randomized trial. J Ophthalmol 2020; 2020:8359398.
El-Sayyad F, El-Saied HMA, Abdelhakim MASE. Trabeculectomy with ologen versus mitomycin C in juvenile open-angle glaucoma: a 1-year study. Ophthalmic Res 2017; 57:230–238.
Wilson SE. Topical losartan: practical guidance for clinical trials in the prevention and treatment of corneal scarring fibrosis and other eye diseases and disorders. J Ocul Pharmacol Ther 2023; 39:191–206.
Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in glaucoma and ocular hypertension (LiGHT) trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology 2023; 130:139–151.